| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,380,000 |
| Market
Cap: |
35.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1 - $1.25 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Evofem Biosciences is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health, including woman-controlled contraception and protection from certain sexually transmitted infections. Co.'s commercial product, Phexxi, is the U.S. Food and Drug Administration (FDA)-approved, hormone-free, woman-controlled, prescription contraceptive gel for women. Co. is evaluating Phexxi for two potential new indications: the prevention of chlamydia and the prevention of gonorrhea in women. The FDA has designated Phexxi, using the investigational name EVO100, as a Qualified Infectious Disease Product.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
141,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$49,703 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
114 |
114 |
114 |
| Total Sell Value |
$0 |
$10 |
$10 |
$10 |
| Total People Sold |
0 |
2 |
2 |
2 |
| Total Sell Transactions |
0 |
2 |
2 |
2 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Link Fund Solutions Ltd |
10% Owner |
– – • |
2020-06-04 |
4 |
S |
$0.23 |
$2,101,856 |
D/D |
(9,138,504) |
0 |
|
- |
|
| Acacia Research Corp |
10% Owner |
– – • |
2020-06-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,139,504 |
|
- |
|
| Acacia Research Corp |
10% Owner |
– – • |
2020-06-04 |
4 |
S |
$3.21 |
$29,325,459 |
D/D |
(9,138,504) |
1,000 |
|
- |
|
| Invesco Ltd. |
10% Owner |
– – • |
2020-05-26 |
4 |
S |
$5.79 |
$427,772 |
I/I |
(73,879) |
12,369,389 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2020-05-22 |
4 |
D |
$4.99 |
$197,040 |
D/D |
(39,487) |
166,042 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2020-05-22 |
4 |
D |
$4.99 |
$97,175 |
D/D |
(19,474) |
308,964 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2020-05-22 |
4 |
D |
$4.99 |
$210,887 |
D/D |
(42,262) |
280,415 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2020-05-22 |
4 |
D |
$4.99 |
$196,781 |
D/D |
(39,435) |
146,999 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2020-05-22 |
4 |
D |
$4.99 |
$421,780 |
D/D |
(84,525) |
564,705 |
|
- |
|
| Pdl Biopharma, Inc. |
10% Owner |
– – • |
2020-05-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,333,334) |
0 |
|
- |
|
| Invesco Ltd. |
10% Owner |
– – • |
2020-05-15 |
4 |
S |
$5.04 |
$16,183 |
I/I |
(3,211) |
12,443,268 |
|
- |
|
| Invesco Ltd. |
10% Owner |
– – • |
2020-05-14 |
4 |
A |
$5.13 |
$400,207 |
I/I |
78,013 |
12,446,479 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2020-05-06 |
4 |
D |
$5.24 |
$40,830 |
D/D |
(7,792) |
186,434 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2020-05-06 |
4 |
D |
$5.24 |
$19,922 |
D/D |
(3,802) |
328,438 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2020-05-06 |
4 |
D |
$5.24 |
$40,882 |
D/D |
(7,802) |
205,529 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2020-05-06 |
4 |
D |
$5.24 |
$44,121 |
D/D |
(8,420) |
322,677 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2020-05-06 |
4 |
D |
$5.24 |
$88,582 |
D/D |
(16,905) |
649,230 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2020-05-01 |
4 |
AS |
$4.75 |
$4,750 |
D/D |
(1,000) |
194,226 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2020-04-30 |
4 |
AS |
$4.66 |
$4,660 |
D/D |
(1,000) |
195,226 |
|
- |
|
| Lynch Thomas G |
Director |
– • – |
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
325,000 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2020-02-19 |
4 |
AS |
$6.50 |
$97,221 |
D/D |
(14,957) |
332,240 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2020-02-19 |
4 |
AS |
$7.00 |
$7,000 |
D/D |
(1,000) |
196,226 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$20,038 |
D/D |
303,846 |
666,135 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$20,038 |
D/D |
153,846 |
331,097 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
213,331 |
|
- |
|
194 Records found
|
|
Page 3 of 8 |
|
|
